PRONEUROGEN INC

Address: 1970 N WENTWORTH RD TUCSON, AZ 85749-9741
County: PIMA
Country: UNITED STATES
UEI: CC75K29RDV48

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2025 ( Subtotal = -$400 )

2025

2023

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG085713

GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular

000

NIH

7/16/2025

2025

2022

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG077967

Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia

000

NIH

12/19/2024

2025

2022

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG079647

Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias

000

NIH

12/19/2024

-$400

Issue Date FY: 2024 ( Subtotal = $0 )

2024

2023

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG085713

GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular

000

NIH

2/16/2024

2024

2022

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG079647

Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias

000

NIH

2/16/2024

2024

2022

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG077967

Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia

000

NIH

2/16/2024

Issue Date FY: 2023 ( Subtotal = $499,545 )

2023

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG085713

GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular

000

NIH

9/15/2023

$499,545

2023

2022

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG077967

Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia

000

NIH

12/6/2022

2023

2022

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG079647

Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias

000

NIH

11/21/2022

2023

2020

PRONEUROGEN INC

1970 N WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG069524

Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment

000

NIH

10/21/2022

Issue Date FY: 2022 ( Subtotal = $999,361 )

2022

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG077967

Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia

000

NIH

9/20/2022

$499,763

2022

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG079647

Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias

000

NIH

8/19/2022

$499,598

2022

2020

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG069524

Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment

000

NIH

10/14/2021

2022

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063674

Novel formulations of Allopregnanolone to treat Alzheimer's Disease

000

NIH

12/20/2021

Issue Date FY: 2021 ( Subtotal = $0 )

2021

2020

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG069524

Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment

000

NIH

10/15/2020

2021

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063674

Novel formulations of Allopregnanolone to treat Alzheimer's Disease

000

NIH

2/12/2021

2021

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063652

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)

000

NIH

3/12/2021

Issue Date FY: 2020 ( Subtotal = $439,355 )

2020

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG069524

Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment

000

NIH

8/5/2020

$439,355

2020

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063674

Novel formulations of Allopregnanolone to treat Alzheimer's Disease

000

NIH

4/30/2020

2020

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063652

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)

000

NIH

4/30/2020

Issue Date FY: 2019 ( Subtotal = $855,301 )

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063652

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)

001

NIH

8/29/2019

$182,560

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063652

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)

000

NIH

6/13/2019

$222,855

2019

PRONEUROGEN, INC.

1970 WENTWORTH RD

TUCSON

85749-9741

PIMA

USA

R43AG063674

Novel formulations of Allopregnanolone to treat Alzheimer's Disease

000

NIH

9/17/2019

$449,886

All Categories

About

Search

Reports

Data Submission

Recipient Information

PRONEUROGEN INC

Address: 1970 N WENTWORTH RD TUCSON, AZ 85749-9741

County: PIMA

Country: UNITED STATES

UEI: CC75K29RDV48

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer